What is Wedbush’s Forecast for VRDN Q1 Earnings?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Equities researchers at Wedbush issued their Q1 2026 earnings per share estimates for Viridian Therapeutics in a report released on Tuesday, November 12th. Wedbush analyst L. Chico forecasts that the company will post earnings per share of ($1.17) for the quarter. Wedbush has a “Outperform” rating and a $42.00 price target on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($3.94) per share. Wedbush also issued estimates for Viridian Therapeutics’ Q2 2026 earnings at ($1.21) EPS, Q3 2026 earnings at ($1.16) EPS and FY2028 earnings at $9.52 EPS.

Other equities analysts also recently issued research reports about the stock. Oppenheimer restated an “outperform” rating and set a $28.00 price objective (down previously from $31.00) on shares of Viridian Therapeutics in a research report on Monday, August 12th. HC Wainwright raised their price objective on shares of Viridian Therapeutics from $27.00 to $34.00 and gave the company a “buy” rating in a research note on Thursday. The Goldman Sachs Group raised their price objective on Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, September 12th. Needham & Company LLC reissued a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a report on Wednesday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $44.00 price target on shares of Viridian Therapeutics in a research note on Thursday, September 19th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $36.33.

Viridian Therapeutics Stock Down 3.7 %

Shares of NASDAQ VRDN opened at $21.64 on Thursday. The company has a quick ratio of 15.82, a current ratio of 15.82 and a debt-to-equity ratio of 0.05. Viridian Therapeutics has a 52-week low of $11.40 and a 52-week high of $27.20. The business has a 50-day moving average price of $22.35 and a 200 day moving average price of $16.89. The stock has a market cap of $1.38 billion, a PE ratio of -5.02 and a beta of 1.10.

Hedge Funds Weigh In On Viridian Therapeutics

A number of hedge funds have recently modified their holdings of VRDN. Hennion & Walsh Asset Management Inc. increased its position in Viridian Therapeutics by 62.9% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 178,855 shares of the company’s stock worth $2,327,000 after purchasing an additional 69,035 shares during the last quarter. Rhumbline Advisers boosted its holdings in Viridian Therapeutics by 34.5% in the second quarter. Rhumbline Advisers now owns 90,826 shares of the company’s stock worth $1,182,000 after purchasing an additional 23,305 shares in the last quarter. Vanguard Group Inc. increased its position in Viridian Therapeutics by 7.8% during the first quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock worth $56,632,000 after buying an additional 233,331 shares during the last quarter. Candriam S.C.A. lifted its holdings in Viridian Therapeutics by 167.8% in the 2nd quarter. Candriam S.C.A. now owns 749,804 shares of the company’s stock worth $9,754,000 after purchasing an additional 469,804 shares during the last quarter. Finally, Novo Holdings A S grew its stake in Viridian Therapeutics by 19.3% in the 3rd quarter. Novo Holdings A S now owns 2,385,000 shares of the company’s stock valued at $54,259,000 after buying an additional 385,000 shares during the last quarter.

Insider Buying and Selling

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc bought 1,600,000 shares of the firm’s stock in a transaction dated Friday, September 13th. The stock was acquired at an average price of $18.75 per share, with a total value of $30,000,000.00. Following the completion of the transaction, the director now directly owns 3,445,813 shares in the company, valued at approximately $64,608,993.75. This represents a 86.68 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Thomas W. Beetham purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average cost of $23.41 per share, for a total transaction of $117,050.00. Following the completion of the transaction, the chief operating officer now directly owns 6,000 shares of the company’s stock, valued at $140,460. This trade represents a 500.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 1,626,400 shares of company stock worth $30,616,312 in the last three months. 0.65% of the stock is currently owned by insiders.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.